We hypothesized that cervix cancer patients with aberrations in this pathway would achieve clinical benefit (defined as objective response and prolonged stable disease) when treated with PI3K/AKT/mTOR pathway targeted agents. This evidence concerns the gene PIK3CB and cervical cancer.